Quality of life in patients with psoriasis and psoriasis arthritis with a special focus on stigmatization experience

Clinics in Dermatology

Volumn 25, Issue 6, 2007, Pages 547-554

  Schmid Ott, Gerhard ^a   Schallmayer, Sabine ^a   Calliess, Iris Tatjana ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DISEASE SEVERITY; HUMAN; MEDICAL SPECIALIST; PATIENT EDUCATION; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; SELF HELP; SEXUALITY; SOCIAL ASPECT; STIGMA;

ARTHRITIS, PSORIATIC; HUMANS; PATIENT EDUCATION AS TOPIC; PSORIASIS; QUALITY OF LIFE; QUESTIONNAIRES; SELF-HELP GROUPS; SEVERITY OF ILLNESS INDEX; STEREOTYPING;

EID: 36049001754     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2007.08.008     Document Type: Article

References (65)

1. Holsinger L. A battle with my skin. J Am Acad Dermatol 51 (2004) 41-42
2. Schön M.P., and Boehncke W.H. Psoriasis. N Engl J Med 352 (2005) 1899-1912
3. Buske-Kirschbaum A., Ebrecht M., Kern S., et al. Endocrine stress responses in TH1-mediated chronic inflammatory skin disease (psoriasis vulgaris)-do they parallel stress-induced endocrine changes in TH2-mediated inflammatory dermatoses (atopic dermatitis)?. Psychoneuroendocrinology 31 (2006) 439-446
4. Schmid-Ott G., Jäger B., Boehm T., et al. Different stress-induced membrane molecule profile of circulating lymphocytes in patients with psoriasis and healthy controls. Psychother Psychos Med Psychol 56 (2006) 104
5. Lebwohl M. Psoriasis. Lancet 361 (2003) 1197-1204
6. Myers W.A., Gottlieb A.B., and Mease P. Psoriasis and psoriatic arthritis: clinical features and disease mechanisms. Clin Dermatol 24 (2006) 438-447
7. Ghoreschi K., Thomas P., Breit S., et al. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med 9 (2003) 40-46
8. Galadari I., Sharif M.O., and Galadari H. Psoriasis: a fresh look. Clin Dermatol 23 (2005) 491-502
9. Crosby I.A. My skin is only the top layer of the problem. Arch Dermatol 131 (1995) 783-785
10. Finlay A.Y., and Khan G.K. Dermatology Life Quality Index DLQI: a simple practical measure for routine clinical use. Clin Exp Dermatol 19 (1994) 210-216
11. Rapp S.R., Feldman S.R., Exum M.L., et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 41 (1999) 401-407
12. Perrott S.B., Murray A.H., Lowe J., et al. The psychosocial impact of psoriasis: physical severity, quality of life, and stigmatization. Physiol Behav 70 (2000) 567-571
13. Wahl A., Loge J.H., Wiklund I., et al. The burden of psoriasis: a study concerning health-related quality of life among Norwegian adult patients with psoriasis compared with general population norms. J Am Acad Dermatol 43 (2000) 803-808
14. Krueger G., Koo J., Lebwohl M., et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 137 (2001) 280-284
15. Touw C.R., Hakkaart-Van Roijen L., Verboom P., et al. Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin. Br J Dermatol 144 (2001) 967-972
16. Koo J., Kozma C.M., and Reinke K. The development of a disease-specific questionnaire to assess quality of life for psoriasis patients: an analysis of reliability, validity, and responsiveness of the psoriasis quality of life questionnaire. Dermatol Psychosom 3 (2003) 171-179
17. Vardy D., Besser A., Amir M., et al. Experiences of stigmatization play a role in mediating the impact of disease severity on quality of life in psoriasis patients. Br J Dermatol 147 (2002) 736-742
18. De Korte J., Mombers F.M., Sprangers M.A., et al. The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review. Arch Dermatol 138 (2002) 1221-1227
19. Zachariae H., Zachariae R., Blomqvist K., et al. Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. Acta Derm Venereol 82 (2002) 108-113
20. Schmid-Ott G., Burchard R., Niederauer H.H., et al. Stigmatization experience and the quality of life of patients with psoriasis and atopic dermatitis. Hautarzt 54 (2003) 852-857
21. Lewis V.J., and Finlay A.Y. A critical review of quality-of-life scales for psoriasis. Dermatol Clin 23 (2005) 707-716
22. Katugampola R.P., Hongbo Y., and Finlay A.Y. Clinical management decisions are related to the impact of psoriasis on patient-rated quality of life. Br J Dermatol 152 (2005) 1256-1262
23. Schmid-Ott G., Kuensebeck H.W., Jaeger B., et al. Significance of the stigmatization experience of psoriasis patients: a 1-year follow-up of the illness and its psychosocial consequences in men and women. Acta Derm Venereol 85 (2005) 27-32
24. Nast A., Kopp I., Augustin M., et al. German S3-guideline for the treatment of psoriasis vulgaris-short version. JDDG (2006) [submitted]
25. Mease P.J., and Menter M.A. Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol 54 (2006) 685-704
26. Passeron T., and Ortonne J.P. Use of the 308-nm excimer laser for psoriasis and vitiligo. Clin Dermatol 24 (2006) 33-42
27. Gupta M.A., and Gupta A.K. The Psoriasis Life Stress Inventory: a preliminary index of psoriasis-related stress. Acta Derm Venereol 75 (1995) 240-243
28. Schmid-Ott G., Kuensebeck H.W., Jaeger B., et al. Validity study for the stigmatization experience in atopic dermatitis and psoriasis patients. Acta Derm Venereol 79 (1999) 443-447
29. Scharloo M., Kaptein A.A., Weinman J., et al. Patients' illness perceptions and coping as predictors of functional status in psoriasis: a 1-year follow-up. Br J Dermatol 142 (2000) 899-907
30. Fortune D.G., Richards H.L., Main C.J., et al. Patients' strategies for coping with psoriasis. Clin Exp Dermatol 27 (2002) 177-184
31. Fortune D.G., Richards H.L., Griffiths C.E., et al. Psychological stress, distress and disability in patients with psoriasis: consensus and variation in the contribution of illness perceptions, coping and alexithymia. Br J Clin Psychol 41 (2002) 157-174
32. Davidsson S., Blomqvist K., Molin L., et al. Lifestyle of Nordic people with psoriasis. Int J Dermatol 44 (2005) 378-383
33. Nijsten T., Rolstad T., Feldman S.R., et al. Members of the national psoriasis foundation: more extensive disease and better informed about treatment options. Arch Dermatol 141 (2005) 19-26
34. Schmid-Ott G., Malewski P., Kreiselmaier I., et al. Psychosocial consequences of psoriasis-an empirical study on the burden of skin disease in 3753 patients. Hautarzt 56 (2005) 466-472
35. Dubertret L., Mrowietz U., Ranki A., et al. EUROPSO Patient Survey Group. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 55 (2006) 729-736
36. Richards H.L., Fortune D.G., Griffiths C.E., et al. The contribution of perceptions of stigmatisation to disability in patients with psoriasis. J Psychosom Res 50 (2001) 11-15
37. Gordon K.B., Papp K.A., Hamilton T.K., et al. Efalizumab Study Group. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 290 (2003) 3073-3080
38. Leonardi C.L., Powers J.L., Matheson R.T., et al. Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349 (2003) 2014-2022
39. Mease P.J., Goffe B.S., Metz J., et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 356 (2000) 385-390
40. Van de Kerkhof P.C. The impact of a two-compound product containing calcipotriol and betamethasone dipropionate (Daivobet/Dovobet) on the quality of life in patients with psoriasis vulgaris: a randomized controlled trial. Br J Dermatol 151 (2004) 663-668
41. Feldman S.R., Gordon K.B., Bala M., et al. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br J Dermatol 152 (2005) 954-960
42. Mease P.J., Gladman D.D., Ritchlin C.T., et al. Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52 (2005) 3279-3289
43. Nash P., Thaci D., Behrens F., et al. Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study. Dermatology 212 (2006) 238-249
44. Kavanaugh A., Antoni C.E., Gladman D., et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis 65 (2006) 1038-1043
45. Zink A., Thiele K., Huscher D., et al. German Collaborative Arthritis Centres. Healthcare and burden of disease in psoriatic arthritis. A comparison with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 33 (2006) 86-90
46. Schmid-Ott G., Jaeger B., Kuensebeck H.W., et al. Dimensions of stigmatization in patients with psoriasis in a "Questionnaire on Experience with Skin Complaints". Dermatology 193 (1996) 304-310
47. Schmid-Ott G., Jaeger B., Kuensebeck H.W., et al. Psychosocial influences on the illness experience of psoriasis patients. A study with the "Questionnaire on Experience with Skin Complaints (QES)". Zeitschr Klin Psychol Psychiat Psychoth 46 (1998) 330-343
48. Ginsburg I.H., and Link B.G. Feelings of stigmatization in patients with psoriasis. J Am Acad Dermatol 20 (1989) 53-63
49. Fortune D.G., Main C.J., O'Sullivan T.M., et al. Assessing illness-related stress in psoriasis: the psychometric properties of the Psoriasis Life Stress Inventory. J Psychosom Res 42 (1997) 467-475
50. Sorensen A.S., Hansen H., Andersen R., et al. Personality characteristics and epilepsy. Acta Psychiatr Scand 80 (1989) 620-631
51. Ginsburg I.H., and Link B.G. Psychosocial consequences of rejection and stigma feelings in psoriasis patients. Int J Dermatol 32 (1993) 587-591
52. Finlay A.Y., and Coles E.C. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 132 (1995) 236-244
53. Kent G., and Al-Abadie M. Factors affecting responses on Dermatology Life Quality Index items among vitiligo sufferers. Clin Exp Dermatol 21 (1996) 330-333
54. Schmid-Ott G., Jaeger B., Kuensebeck H.W., et al. Illness attitudes and help seeking of psoriasis patients. Hautarzt Der 48 (1997) 547-555
55. Gupta M.A., Gupta A.K., and Watteel G.N. Perceived deprivation of social touch in psoriasis is associated with greater psychologic morbidity: an index of the stigma experience in dermatologic disorders. Cutis 61 (1998) 339-342
56. Leary M.R., Rapp S.R., Herbst K.C., et al. Interpersonal concerns and psychological difficulties of psoriasis patients: effects of disease severity and fear of negative evaluation. Health Psychol 17 (1998) 530-536
57. Schmid-Ott G., Malewski P., Kuensebeck H.W., et al. Illness-related stress in psoriasis vulgaris. Validation of the "Psoriasis Daily Stress Inventory". Hautarzt 51 (2000) 496-501
58. Weiss S.C., Kimball A.B., Liewehr D.J., et al. Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol 47 (2002) 512-518
59. Nijsten T., Unaeze J., and Stern R.S. Refinement and reduction of the Impact of Psoriasis Questionnaire: classical test theory vs. Rasch analysis. Br J Dermatol 154 (2006) 692-700
60. Jobling R., and Naldi L. Assessing the impact of psoriasis and the relevance of qualitative research. J Invest Dermatol 126 (2006) 1438-1440
61. Grob J.J., Revuz J., Ortonne J.P., et al. Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life. Br J Dermatol 152 (2005) 289-295
62. Fredriksson T., and Petersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 157 (1978) 238-244
63. Feldman S.R., Fleischer A.B., Reboussin D.M., et al. The self-administered psoriasis area and severity index is valid and reliable. J Invest Dermatol 106 (1996) 183-186
64. Staab D., Diepgen T.L., Fartasch M., et al. Age related, structured education programmes improve the management of atopic dermatitis in children and adolescents: results of the German Atopic Dermatitis Intervention Study (GADIS). Br Med J 332 (2006) 933-938
65. Bonnekoh B., Schmid-Ott G., Herold S., et al. Interdisciplinary block school-program for educational psoriasis prevention in adult patients: a half-year follow-up. Hautarzt 57 (2006) 917-922